Why the study?
Does transcatheter edge-to-edge repair of the mitral valve reduce hospitalization for heart failure and mortality in patients with heart failure, reduced LVEF, and moderate-to-severe or severe secondary mitral regurgitation?
Does transcatheter edge-to-edge repair of the mitral valve reduce hospitalization for heart failure and mortality in patients with heart failure, reduced LVEF, and moderate-to-severe or severe secondary mitral regurgitation?
Discusses the long-term maintenance of reductions in heart failure hospitalization and mortality following transcatheter edge-to-edge repair for secondary mitral regurgitation.
A key question after the publication of the primary results of the COAPT trial (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation)1 was whether the striking reductions in the rate of hospitalization for heart failure and mortality over a period of 24 months would be maintained in the longer term. In this trial, 614 patients with heart failure, a reduced left ventricular ejection fraction, and moderate-to-severe or severe secondary (or functional) mitral regurgitation were randomly assigned in a 1:1 ratio either to undergo transcatheter edge-to-edge repair of the mitral valve in addition . . .
No takes yet. Share an insight, caveat, or question.
McMurray et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: